Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Request To Download Free Sample of This Strategic Report @- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...

Symptoms include a chronic cough, shortness of breath ... outlicensed a portfolio of programmes (two in clinical trials) to Merck Germany that are first-in-class treatments for multiple types ...